Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Issue 13 (3rd July 2018)

• Record Type: Journal Article
• Authors: Chen, Hongjie; McGowan, Eileen M; Ren, Nina; Lal, Sara; Nassif, Najah; Shad-Kaneez, Fatima; Qu, Xianqin; Lin, Yiguang
• Is Part Of: Biomarker insights. Volume 2018:Issue 13(2018)
• Publication Date: 2018-07-03
• Subjects: Nattokinase -- natto -- cardiovascular disease -- antithrombotic agents -- antihypertensive drugs -- atherosclerosis; Biochemical markers -- Periodicals; 572.43
• DOI: 10.1177/1177271918785130
• Languages: English
• ISSNs: 1177-2719

Abstract

Cardiovascular disease (CVD) is the leading cause of death in the world and our approach to the control and management of CVD mortality is limited. Nattokinase (NK), the most active ingredient of natto, possesses a variety of favourable cardiovascular effects and the consumption of Natto has been linked to a reduction in CVD mortality. Recent research has demonstrated that NK has potent fibrinolytic activity, antihypertensive, anti-atherosclerotic, and lipid-lowering, antiplatelet, and neuroprotective effects. This review covers the major pharmacologic effects of NK with a focus on its clinical relevance to CVD. It outlines the advantages of NK and the outstanding issues pertaining to NK pharmacokinetics. Available evidence suggests that NK is a unique natural compound that possesses several key cardiovascular beneficial effects for patients with CVD and is therefore an ideal drug candidate for the prevention and treatment of CVD. Nattokinase is a promising alternative in the management of CVD.